Drug intelligence / Profile preview

CH505 TF mRNA-gp160

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CH505 TF mRNA-gp160 is an investigational mRNA vaccine being developed for HIV prevention. It consists of mRNA encoding the HIV envelope glycoprotein gp160 from the CH505 transmitter founder (TF) virus, encapsulated in lipid nanoparticles (LNPs).

Targets

BCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)

Beyond the preview

Go deeper on CH505 TF mRNA-gp160.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CH505 TF mRNA-gp160.

Explore the full profile